BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination- Vote in favor of the handheld vacuum that you love for its strong attractions!
- A Manual for Pick High Evaluated Food Conveyance Administrations In Significant Urban communities For 2024
- Presenting Nintendo's New Pastel Euphoria Con Tones for Switch Gamers: 3 Trendy Choices
- Here's what can happen if you drive under the influence of pot
- Most loved Road Food: Which One Prevails upon You?
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Astronomer captures 2 meteors slamming into the moon (video)
- Instructions to Arrange Your Compensation During Medical caretaker Prospective employee meetings
